FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
about
Aristolochic acid-associated urothelial cancer in TaiwanPrognostic Genetic Signatures in Upper Tract Urothelial CarcinomaRisk stratification for kidney sparing procedure in upper tract urothelial carcinomaRole of angiogenesis in urothelial bladder carcinomaThe association between the TERT rs2736100 AC genotype and reduced risk of upper tract urothelial carcinomas in a Han Chinese populationA place for precision medicine in bladder cancer: targeting the FGFRs.Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.Integrated epigenome profiling of repressive histone modifications, DNA methylation and gene expression in normal and malignant urothelial cells.MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer.Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing.Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature.TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCRTERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.Genomic Characterization of Upper Tract Urothelial CarcinomaA noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuriaAdjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: updated results of the Seoul National University Hospital experienceNoninvasive multianalyte diagnostic assay for monitoring bladder cancer recurrence.The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients.EORTC risk tables - their usefulness in the assessment of recurrence and progression risk in non-muscle-invasive bladder cancer in Polish patients.Global epigenetic profiling in bladder cancer.Urothelial cancers: using biology to improve outcomes.Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.Molecular targets on the horizon for kidney and urothelial cancer.Urinary biomarkers of bladder cancer: an update and future perspectives.Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?The route to personalized medicine in bladder cancer: where do we stand?Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review.Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges.A noninvasive multi-analyte diagnostic assay: combining protein and DNA markers to stratify bladder cancer patientsMolecular grading of tumors of the upper urothelial tract using FGFR3 mutation status identifies patients with favorable prognosis.FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.Tissue-based molecular markers in upper tract urothelial carcinoma and their prognostic implications.The plasmacytoid carcinoma of the bladder--rare variant of aggressive urothelial carcinoma.
P2860
Q24616582-E5C162E9-AD5F-4058-B77F-98157B88DEC7Q26772220-B3525E4D-E28D-4292-B784-4A6D2907ABD2Q28077825-84B43FE7-E589-41C9-9AE3-638814C14447Q28080330-B646C233-5D1B-440E-9604-84B829B91C3CQ28392404-122C478D-64B6-4219-975D-9C2D46DC2192Q30249143-0FEA524F-3D23-4F61-984F-2AA7A14FDC9DQ30857433-519F6361-0DE3-4B5B-9B00-78588794C0B4Q33526301-565EC551-AC69-4804-BC08-16469470AC01Q33745140-7916D643-0B02-4E70-A659-B5E809195582Q34193379-24DBEA44-302C-4C6B-AE2F-633E557152FDQ34227727-A18AA19C-41FF-4D5D-A63C-BD26FFF863FFQ34362617-4D9B5F07-145C-4660-B850-41124EC86198Q34579038-75204701-58F1-44FA-92DC-3B7146996A34Q35068013-CA2B255B-4B39-4262-8F68-C1A7305EAEB1Q35151119-27FC7D90-66B4-42CC-BDCA-6E2FF7C5A4DFQ36362571-A4305352-BD18-4A37-A8D7-34E92E2EF959Q36513100-785D84E0-24A3-4869-A62D-6C61D0DC0C95Q36589221-3CB678FD-9CAE-41B3-B847-979314E4D693Q37250675-2684CE38-71EB-4F47-A1E3-D5863711CF33Q37295512-ACD6C03E-2949-471E-B3FB-5D301C0DB163Q37579231-A93E0A7B-DCD7-43EA-A966-E6E40927ECE3Q37962571-BF2C32B6-6725-459A-B847-CBFD4E023C18Q37965638-109F1976-BDC8-41D2-8F77-E544F097674CQ38044251-8CCC90BB-EB3E-4B50-B9D2-45742CF9BAD0Q38132039-499B05E9-E34B-44CF-8A6A-64B308CCAAA5Q38138607-3819BCB8-34E1-4F7C-89A5-DA144DBDE356Q38312045-5BE35D79-0718-4FFE-8735-40D746CE73FAQ38337192-FB84E76C-FC98-49F2-B562-CD51C3F96C33Q38814000-CEC29B10-6567-44BB-874B-0CDC183F9E94Q39078873-EE95A867-8038-46C9-9326-A8EB1F2AA731Q39568069-DDBDA32F-AADF-404C-8C18-521515992A22Q41833981-FBD59552-4754-4AB3-995D-B4E1FBC46F07Q42936872-FE8CED53-F006-4281-88F8-426C35360BEDQ43115752-EAE0A441-2AD9-4BA6-8F5D-D9820064DACEQ50032108-4C922CC7-C35D-4048-9D33-33906BF593CEQ54647137-8D8476B2-3386-4953-A001-14881155997B
P2860
FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
FGFR3 mutations indicate bette ...... ary tract and bladder tumours.
@ast
FGFR3 mutations indicate bette ...... ary tract and bladder tumours.
@en
type
label
FGFR3 mutations indicate bette ...... ary tract and bladder tumours.
@ast
FGFR3 mutations indicate bette ...... ary tract and bladder tumours.
@en
prefLabel
FGFR3 mutations indicate bette ...... ary tract and bladder tumours.
@ast
FGFR3 mutations indicate bette ...... ary tract and bladder tumours.
@en
P2093
P1433
P1476
FGFR3 mutations indicate bette ...... nary tract and bladder tumours
@en
P2093
Abdel-Rahmene Azzouzi
Ellen C Zwarthoff
Freddie C Hamdy
Ishtiaq Rehman
Johanna M M van Oers
Mark Meuth
P304
P356
10.1016/J.EURURO.2008.06.013
P407
P577
2008-06-13T00:00:00Z